Dexamethasone
Drugpatients will receive intrathecal dexamethasone 8 mg in 3 ml volume.
NCT Number: NCT06752317
Postoperative Ileus (POI) is considered as intolerance of oral intake due to disruption of the normal coordinated propulsive motor activity of the gastrointestinal (GI) tract following abdominal or non-abdominal surgery.
Dexamethasone & Dexmedetomidine have been reported to attenuate the incidence of paralytic ileus after abdominal surgeries.
Previous study has shown that a single dose of DM before induction of anesthesia may be beneficial to reduce ileus for IBD by alleviating the postoperative systemic inflammatory response.
Perioperative dexmedetomidine in major abdominal surgeries significantly decreased the time to flatus, defecation, and resuming normal diet, shortened length of stay, and improved haemodynamic stability.
The aim of this study is to compare the effect of preoperative intrathecal dexamethasone versus dexmedetomidine on paralytic ileus after major abdominal surgery.
Trial opening soon.
Get Notified18 year–60 year
All sexes
Interventional
Phase 4
Postoperative Ileus (POI) is considered as intolerance of oral intake due to disruption of the normal coordinated propulsive motor activity of the gastrointestinal (GI) tract following abdominal or non-abdominal surgery.
Dexamethasone & Dexmedetomidine have been reported to attenuate the incidence of paralytic ileus after abdominal surgeries.
Previous study has shown that a single dose of DM before induction of anesthesia may be beneficial to reduce ileus for IBD by alleviating the postoperative systemic inflammatory response.
Perioperative dexmedetomidine in major abdominal surgeries significantly decreased the time to flatus, defecation, and resuming normal diet, shortened length of stay, and improved haemodynamic stability.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
patients will receive intrathecal dexamethasone 8 mg in 3 ml volume.
patients will receive intrathecal dexmedetomidine 0.5 µg/kg in 3 ml volume.
Time frame: 24 hours
number of participants who had experienced vomiting on day 1.
Contact information is provided by the study sponsor or research team.
Assiut University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03884244
Digestive System Diseases, Female Urogenital Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06113718
Defecation Disorder, Digestive System Diseases
Izmir, Konak, Turkey (Türkiye)
View Trial DetailsNCT01131416
Digestive System Diseases, Gastrointestinal Diseases
Chiang Mai, Thailand
View Trial DetailsNCT06687564
Digestive System Diseases, Gastrointestinal Diseases
Montpellier, France
View Trial Details